Atkins H L, Srivastava S C
Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA.
Q J Nucl Med. 1996 Sep;40(3):285-9.
Bone seeking radiopharmaceuticals consist of diagnostic (primarily single photon emitters) and therapeutic agents. The therapeutic radiopharmaceuticals are utilized on the basis of their particulate emissions (primarily beta-) and thus are treated differently than the single photon bone imaging agents. Lately, the therapeutic bone seekers have attained increasing importance due to their potential role in alleviating pain from osseous metastases in cancer patients. However, there seems to be a paucity of published data on the pharmacokinetics of most of these agents. This paper will briefly review and summarize the presently available pharmacokinetic information on the various therapeutic bone seeking radiopharmaceuticals. Bone imaging agents based on single photon emitters will not be covered since they have been extensively discussed in the published literature.
亲骨性放射性药物包括诊断性药物（主要是单光子发射体）和治疗性药物。治疗性放射性药物是基于其粒子发射（主要是β粒子）来使用的，因此其处理方式与单光子骨显像剂不同。最近，治疗性亲骨性药物因其在减轻癌症患者骨转移疼痛方面的潜在作用而变得越来越重要。然而，关于这些药物中大多数药物的药代动力学，似乎缺乏已发表的数据。本文将简要回顾和总结目前关于各种治疗性亲骨性放射性药物的药代动力学信息。基于单光子发射体的骨显像剂将不涉及，因为它们在已发表的文献中已有广泛讨论。
